{"id":"ervebo-rvsv-g-zebov-gp","safety":{"commonSideEffects":[{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine uses a replication-competent VSV vector with the VSV glycoprotein replaced by Ebola virus glycoprotein (ZEBOV-GP). This allows the vaccine to replicate and trigger both cellular and humoral immune responses against Ebola virus without causing disease. The rVSV backbone is attenuated and generally well-tolerated, while the inserted Ebola glycoprotein serves as the immunogenic target.","oneSentence":"ERVEBO is a live attenuated recombinant vesicular stomatitis virus (rVSV) vaccine expressing Ebola virus glycoprotein that primes the immune system to recognize and respond to Ebola virus infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:29.748Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of Ebola virus disease caused by Zaire ebolavirus (ZEBOV)"}]},"trialDetails":[{"nctId":"NCT05959421","phase":"PHASE3","title":"Immunity Induced by VSV-EBOV and Assessment of a Booster Dose in Individuals at Potential Occupational Risk for Exposure","status":"NOT_YET_RECRUITING","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2026-06","conditions":"Ebola Vaccine","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ERVEBO® (rVSV∆G-ZEBOV-GP)","genericName":"ERVEBO® (rVSV∆G-ZEBOV-GP)","companyName":"Universitätsklinikum Hamburg-Eppendorf","companyId":"universit-tsklinikum-hamburg-eppendorf","modality":"Biologic","firstApprovalDate":"","aiSummary":"ERVEBO is a live attenuated recombinant vesicular stomatitis virus (rVSV) vaccine expressing Ebola virus glycoprotein that primes the immune system to recognize and respond to Ebola virus infection. Used for Prevention of Ebola virus disease caused by Zaire ebolavirus (ZEBOV).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}